Abstract
To prevent acquisition of HIV through oral sex, drugs used for preexposure prophylaxis (Prep) need to diffuse in saliva. We measured tenofovir (TFV) and emtricitabine (FTC) concentrations simultaneously in the plasma and saliva of 41 HIV-infected patients under stable antiretroviral treatment. Mean ratios of saliva/plasma concentration were 3% (±4%) and 86.9% (±124%) for TFV and FTC, respectively. Tenofovir disoproxil fumarate (TDF) should be used in combination with FTC to prevent oral acquisition of HIV.
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adenine / analysis
-
Adenine / blood
-
Adenine / therapeutic use
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / analysis*
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / therapeutic use
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / analysis
-
Deoxycytidine / blood
-
Deoxycytidine / therapeutic use
-
Drug Therapy, Combination
-
Emtricitabine
-
HIV Infections / drug therapy
-
HIV Infections / prevention & control*
-
HIV Infections / transmission
-
HIV-1 / drug effects
-
Humans
-
Male
-
Middle Aged
-
Organophosphonates / administration & dosage
-
Organophosphonates / analysis*
-
Organophosphonates / blood
-
Organophosphonates / therapeutic use
-
Saliva / chemistry*
-
Sexual Behavior
-
Tenofovir
Substances
-
Anti-HIV Agents
-
Organophosphonates
-
Deoxycytidine
-
Tenofovir
-
Emtricitabine
-
Adenine